Treatment of Acute Otitis Media
High-dose amoxicillin (80-90 mg/kg/day in 2 divided doses) is the first-line antibiotic for acute otitis media in children who have not received amoxicillin in the past 30 days, do not have concurrent purulent conjunctivitis, and are not penicillin-allergic. 1
Initial Management Decision: Antibiotics vs. Observation
The decision to treat immediately with antibiotics versus observation depends on three key factors:
Immediate Antibiotic Treatment Required For:
- All children 6-23 months with bilateral AOM (regardless of severity) 1
- Any child with severe AOM: moderate-to-severe otalgia OR fever ≥39°C (102.2°F) 1
- Any child with otorrhea (perforation with drainage) 1
Observation Option (48-72 hours) Acceptable For:
- Unilateral AOM in children 6-23 months with mild otalgia <48 hours AND temperature <39°C 1
- Any AOM (bilateral or unilateral) in children ≥24 months with mild otalgia <48 hours AND temperature <39°C 1
Critical caveat: Observation requires reliable follow-up mechanism and parent agreement. If either is uncertain, prescribe antibiotics immediately 1.
First-Line Antibiotic Selection
Standard First-Line: Amoxicillin
- Dose: 80-90 mg/kg/day divided twice daily 1
- Duration: 10 days for children <2 years; 5-7 days for children ≥2 years with uncomplicated AOM 1
- Rationale: Effective against S. pneumoniae (including intermediately resistant strains), safe, inexpensive, narrow spectrum, acceptable taste 1
First-Line Alternative: Amoxicillin-Clavulanate
Use high-dose amoxicillin-clavulanate (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate in 2 divided doses—14:1 ratio formulation) when: 1
- Child received amoxicillin in past 30 days
- Concurrent purulent conjunctivitis present
- History of recurrent AOM unresponsive to amoxicillin
The 14:1 ratio formulation causes less diarrhea than other amoxicillin-clavulanate preparations 1.
Penicillin Allergy Alternatives
For non-type I (non-anaphylactic) penicillin allergy: 1
- Cefdinir: 14 mg/kg/day in 1-2 doses
- Cefuroxime: 30 mg/kg/day in 2 doses
- Cefpodoxime: 10 mg/kg/day in 2 doses
These cephalosporins have distinct chemical structures with minimal cross-reactivity risk 1.
For type I hypersensitivity (anaphylaxis): Consider macrolides, though amoxicillin is more effective than macrolides per evidence review 2.
Treatment Failure Management
Reassess at 48-72 hours if symptoms worsen or fail to improve 1.
Second-Line Treatment Algorithm:
If initially treated with amoxicillin:
- Switch to high-dose amoxicillin-clavulanate (90 mg/kg/day amoxicillin) 1
If initially treated with amoxicillin-clavulanate or oral cephalosporins:
- Ceftriaxone 50 mg/kg IM/IV daily for 3 days (superior to 1-day regimen) 1
Third-Line for Multiple Failures:
Consider tympanocentesis for culture and susceptibility testing 1. If unavailable:
- Clindamycin (30-40 mg/kg/day in 3 doses) ± third-generation cephalosporin for H. influenzae/M. catarrhalis coverage 1
Critical warning: S. pneumoniae serotype 19A is often multidrug-resistant and may not respond to clindamycin 1. For repeated failures with multidrug-resistant organisms, consult infectious disease and otolaryngology before using non-FDA-approved agents like levofloxacin or linezolid 1.
Agents to Avoid
Do NOT use trimethoprim-sulfamethoxazole or erythromycin-sulfisoxazole for treatment failures—pneumococcal resistance to these agents is substantial 1.
Pain Management
Treat pain as a standard component of care regardless of antibiotic decision 1. Topical analgesics may reduce ear pain within 10-30 minutes, though evidence quality is low 2.
Follow-Up Considerations
Routine 10-14 day follow-up visits are not evidence-based for all children 1. Persistent middle ear effusion occurs in 60-70% at 2 weeks, 40% at 1 month, and 10-25% at 3 months after successful treatment—this represents otitis media with effusion (OME), not treatment failure, and does not require antibiotics 1.
Recent large-scale data confirms amoxicillin has lower treatment failure and recurrence rates (1.7%) compared to amoxicillin-clavulanate (11.3%), cefdinir (10.0%), and azithromycin (9.8%), supporting its continued first-line status 3.